Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?

Do you bridge with chemotherapy between a course of immunotherapy and the use of targeted therapy in NSCLC?

• Yes, before starting EGFR TKIs
• Yes, before starting ALK TKIs
• Yes, before starting BRAF inhibitors
• Yes, before starting KRAS G12C inhibitors
• Yes, before starting MET inhibitors
• Yes, before starting ROS1 inhibitors
• Yes, before starting RET inhibitors
• Yes, before starting essentially any targeted therapies
• No, I do not typically bridge with chemotherapy before targeted therapy
• Other